source
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...Endpoints · 1mo ago↗ source
- FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public HealthThe U.S. Food and Drug Administration today issued a proposed rule that, if finalized, would help protect the public health of Americans, including youth, by strengthening the agency’s ability to e…fda press · 1mo ago↗ source
- De-Risking a Rare Disease Launch Starts with PrecisionWhy traditional models fall short in rare disease commercialization—and what works instead.